

Nicole C T Van Grieken

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2390600/publications.pdf>

Version: 2024-02-01

82
papers

7,165
citations

172457

29
h-index

74163

75
g-index

82
all docs

82
docs citations

82
times ranked

9858
citing authors

#	ARTICLE	IF	CITATIONS
1	Gastric cancer. <i>Lancet</i> , The, 2020, 396, 635-648.	13.7	2,084
2	Direct detection of early-stage cancers using circulating tumor DNA. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	808
3	Genome-wide cell-free DNA fragmentation in patients with cancer. <i>Nature</i> , 2019, 570, 385-389.	27.8	764
4	Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline <i>CDH1</i> mutation carriers. <i>Journal of Medical Genetics</i> , 2015, 52, 361-374.	3.2	479
5	Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 616-628.	10.7	397
6	Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas. <i>Gut</i> , 2015, 64, 1721-1731.	12.1	197
7	Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS). <i>BMC Cancer</i> , 2011, 11, 329.	2.6	175
8	White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer. <i>Nature Communications</i> , 2020, 11, 525.	12.8	158
9	Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT). <i>Clinical Cancer Research</i> , 2021, 27, 3351-3359.	7.0	143
10	Comprehensive genomic meta-analysis identifies intra-tumoural stroma as a predictor of survival in patients with gastric cancer. <i>Gut</i> , 2013, 62, 1100-1111.	12.1	139
11	Lack of microRNA-101 causes E-cadherin functional deregulation through EZH2 up-regulation in intestinal gastric cancer. <i>Journal of Pathology</i> , 2012, 228, 31-44.	4.5	125
12	CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer. <i>BMC Cancer</i> , 2018, 18, 877.	2.6	115
13	Sialic acids in pancreatic cancer cells drive tumour-associated macrophage differentiation via the Siglec receptors Siglec-7 and Siglec-9. <i>Nature Communications</i> , 2021, 12, 1270.	12.8	111
14	A multi-centred randomised trial of radical surgery versus adjuvant chemoradiotherapy after local excision for early rectal cancer. <i>BMC Cancer</i> , 2016, 16, 513.	2.6	76
15	Outcomes and Treatment Options for Duodenal Adenocarcinoma: A Systematic Review and Meta-Analysis. <i>Annals of Surgical Oncology</i> , 2018, 25, 2681-2692.	1.5	74
16	Biopsy Strategies for Endoscopic Surveillance of Pre-malignant Gastric Lesions. <i>Helicobacter</i> , 2010, 15, 259-264.	3.5	65
17	Genomic landscape of metastatic colorectal cancer. <i>Nature Communications</i> , 2014, 5, 5457.	12.8	61
18	A multicenter randomized phase III trial of neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy in resectable gastric cancer: First results from the CRITICS study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4000-4000.	1.6	59

#	ARTICLE	IF	CITATIONS
19	VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or Tj ETQq1 1 0.284314 rgBT /Overlo	12.8	55
20	Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy. <i>Nature Communications</i> , 2018, 9, 4112.	5.1	53
21	pT4 stage II and III colon cancers carry the worst prognosis in a nationwide survival analysis. Shepherd's local peritoneal involvement revisited. <i>International Journal of Cancer</i> , 2014, 135, 467-478.	6.9	51
22	DPHL: A DIA Pan-human Protein Mass Spectrometry Library for Robust Biomarker Discovery. <i>Genomics, Proteomics and Bioinformatics</i> , 2020, 18, 104-119.	1.0	45
23	Laparoscopic Sentinel Lymph Node Identification in Patients with Colon Carcinoma Using a Near-Infrared Dye: Description of a New Technique and Feasibility Study. <i>Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A</i> , 2013, 23, 367-371.	4.4	43
24	Performance of amplicon-based next generation DNA sequencing for diagnostic gene mutation profiling in oncopathology. <i>Cellular Oncology (Dordrecht)</i> , 2014, 37, 353-361.	1.8	42
25	Apelin: A putative novel predictive biomarker for bevacizumab response in colorectal cancer. <i>Oncotarget</i> , 2017, 8, 42949-42961.	1.3	40
26	Distinct chromosomal aberrations in Epstein-Barr virus-carrying gastric carcinomas tested by comparative genomic hybridization. <i>Gastroenterology</i> , 2001, 121, 612-618.	4.5	39
27	Helicobacter pylori-related and -non-related gastric cancers do not differ with respect to chromosomal aberrations. <i>Journal of Pathology</i> , 2000, 192, 301-306.	6.4	34
28	Loss of KCNQ1 expression in stage II and stage III colon cancer is a strong prognostic factor for disease recurrence. <i>British Journal of Cancer</i> , 2016, 115, 1565-1574.	3.7	33
29	Combined Expression of Plasma Thrombospondin-2 and CA19-9 for Diagnosis of Pancreatic Cancer and Distal Cholangiocarcinoma: A Proteome Approach. <i>Oncologist</i> , 2020, 25, e634-e643.	2.4	31
30	Phosphotyrosine-based-phosphoproteomics scaled-down to biopsy level for analysis of individual tumor biology and treatment selection. <i>Journal of Proteomics</i> , 2017, 162, 99-107.	4.3	31
31	¹⁸ F-Fludeoxyglucose-Positron Emission Tomography/Computed Tomography and Laparoscopy for Staging of Locally Advanced Gastric Cancer. <i>JAMA Surgery</i> , 2021, 156, e215340.	7.0	30
32	Chromosome 5q Loss in Colorectal Flat Adenomas. <i>Clinical Cancer Research</i> , 2012, 18, 4560-4569.	1.9	29
33	IBD-Associated Dysplastic Lesions Show More Chromosomal Instability Than Sporadic Adenomas. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 167-180.	4.2	28
34	Effect of Hospital Volume With Respect to Performing Gastric Cancer Resection on Recurrence and Survival. <i>Annals of Surgery</i> , 2019, 270, 1096-1102.	4.2	27
35	Surgicopathological Quality Control and Protocol Adherence to Lymphadenectomy in the CRITICS Gastric Cancer Trial. <i>Annals of Surgery</i> , 2018, 268, 1008-1013.	5.1	26
36	Increased risk of esophageal squamous cell carcinoma in patients with gastric atrophy: Independent of the severity of atrophic changes. <i>International Journal of Cancer</i> , 2009, 124, 2135-2138.		

#	ARTICLE	IF	CITATIONS
37	Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab. <i>Journal of Clinical Oncology</i> , 2018, 36, 2052-2060.	1.6	26
38	Iron Deficiency After Non-“Small Cell Lung Cancer. <i>Gastroenterology</i> , 2012, 142, e3-e4.	1.3	23
39	Why is colon cancer survival improving by time? A nationwide survival analysis spanning 35 years. <i>International Journal of Cancer</i> , 2017, 141, 531-539.	5.1	22
40	Circulating Tumor DNA Analysis: Clinical Implications for Colorectal Cancer Patients. A Systematic Review. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz042.	2.9	22
41	Rapid quantitative assessment of gastric corpus atrophy in tissue sections. <i>Journal of Clinical Pathology</i> , 2001, 54, 63-69.	2.0	21
42	Comprehensive Mutation Analysis in Colorectal Flat Adenomas. <i>PLoS ONE</i> , 2012, 7, e41963.	2.5	20
43	Combination of a six microRNA expression profile with four clinicopathological factors for response prediction of systemic treatment in patients with advanced colorectal cancer. <i>PLoS ONE</i> , 2018, 13, e0201809.	2.5	20
44	Synoptic reporting increases quality of upper gastrointestinal cancer pathology reports. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 475, 255-259.	2.8	20
45	A phase II feasibility trial of neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma: The PERFECT trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4045-4045.	1.6	20
46	Decoy receptor 1 (DCR1) promoter hypermethylation and response to irinotecan in metastatic colorectal cancer. <i>Oncotarget</i> , 2017, 8, 63140-63154.	1.8	19
47	Non responders to neoadjuvant chemoradiation for esophageal cancer: why better prediction is necessary. <i>Journal of Thoracic Disease</i> , 2017, 9, S843-S850.	1.4	17
48	Unravelling the Diagnostic Dilemma: A MicroRNA Panel of Circulating MiR-16 and MiR-877 as A Diagnostic Classifier for Distal Bile Duct Tumors. <i>Cancers</i> , 2019, 11, 1181.	3.7	16
49	Interferon- and STING-independent induction of type I interferon stimulated genes during fractionated irradiation. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 161.	8.6	16
50	Circulating Tumor DNA as a Preoperative Marker of Recurrence in Patients with Peritoneal Metastases of Colorectal Cancer: A Clinical Feasibility Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 1738.	2.4	15
51	Prospective impact of tumor grade assessment in biopsies on tumor stage and prognostic grouping in gastroesophageal adenocarcinoma. <i>Cancer</i> , 2012, 118, 349-357.	4.1	14
52	Interobserver, intraobserver, and interlaboratory variability in reporting pT4a colon cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 476, 219-230.	2.8	12
53	Prognostic value of tumor markers and ctDNA in patients with resectable gastric cancer receiving perioperative treatment: results from the CRITICS trial. <i>Gastric Cancer</i> , 2022, 25, 401-410.	5.3	12
54	Kinase Inhibitor Treatment of Patients with Advanced Cancer Results in High Tumor Drug Concentrations and in Specific Alterations of the Tumor Phosphoproteome. <i>Cancers</i> , 2020, 12, 330.	3.7	11

#	ARTICLE	IF	CITATIONS
55	Tumor-immune landscape patterns before and after chemoradiation in resectable esophageal adenocarcinomas. <i>Journal of Pathology</i> , 2022, 256, 282-296.	4.5	11
56	Outcome of Colorectal Cancer Patients Treated with Combination Bevacizumab Therapy: A Pooled Retrospective Analysis of Three European Cohorts from the Angiopredict Initiative. <i>Digestion</i> , 2016, 94, 129-137.	2.3	10
57	Irreversible Electroporation to Treat Malignant Tumor Recurrences Within the Pelvic Cavity: A Case Series. <i>CardioVascular and Interventional Radiology</i> , 2017, 40, 1631-1640.	2.0	10
58	Towards Personalization in the Curative Treatment of Gastric Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 614907.	2.8	10
59	Response to neoadjuvant chemotherapy and survival in molecular subtypes of resectable gastric cancer: a post hoc analysis of the D1/D2 and CRITICS trials. <i>Gastric Cancer</i> , 2022, 25, 640-651.	5.3	10
60	Quantitative assessment of gastric corpus atrophy in subjects using omeprazole: a randomized follow-up study. <i>American Journal of Gastroenterology</i> , 2001, 96, 2882-2886.	0.4	9
61	MACROD2 expression predicts response to 5-FU-based chemotherapy in stage III colon cancer. <i>Oncotarget</i> , 2018, 9, 29445-29452.	1.8	9
62	Molecular profiles of response to neoadjuvant chemoradiotherapy in oesophageal cancers to develop personalized treatment strategies. <i>Molecular Oncology</i> , 2021, 15, 901-914.	4.6	7
63	EORTC 1707 VESTIGE: Adjuvant immunotherapy in patients with resected gastric cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1): An open-label randomized controlled phase II study.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS467-TPS467.	1.6	7
64	Risk Factors for Metachronous Isolated Peritoneal Metastasis after Preoperative Chemotherapy and Potentially Curative Gastric Cancer Resection: Results from the CRITICS Trial. <i>Cancers</i> , 2021, 13, 4626.	3.7	6
65	Molecular pathways in post-colonoscopy versus detected colorectal cancers: results from a nested case-control study. <i>British Journal of Cancer</i> , 2022, 126, 865-873.	6.4	6
66	Combination of variations in inflammation- and endoplasmic reticulum-associated genes as putative biomarker for bevacizumab response in KRAS wild-type colorectal cancer. <i>Scientific Reports</i> , 2020, 10, 9778.	3.3	5
67	ImmunoPET imaging with 89Zr-cetuximab in patients with advanced colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 11102-11102.	1.6	2
68	Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases: The randomized phase III CAIRO5 study of the Dutch Colorectal Cancer Group.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS3622-TPS3622.	1.6	2
69	EORTC-1203: Integration of trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy (CT) of HER-2 positive stomach cancer-INNOVATION trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS4133-TPS4133.	1.6	2
70	Identification of a novel predictive genomic biomarker for response to combination bevacizumab in metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 3580-3580.	1.6	2
71	Quality of life in the CRITICS study, a multicenter randomized phase III trial of neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy in resectable gastric cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4060-4060.	1.6	2
72	Circulating tumor DNA dynamics in resectable gastric cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4069-4069.	1.6	2

#	ARTICLE	IF	CITATIONS
73	A comparison of elderly versus nonelderly patients in the CRITICS gastric cancer trial.. Journal of Clinical Oncology, 2019, 37, 81-81.	1.6	1
74	A machine-learning approach for the identification of highly predictive germline SNPs as biomarkers for response to bevacizumab in metastatic colorectal cancer using Elastic Net and Lasso.. Journal of Clinical Oncology, 2018, 36, e15584-e15584.	1.6	1
75	Predictive value of chromosome 18q11.2–12.1 loss for benefit from bevacizumab in metastatic colorectal cancer: A post hoc analysis of the randomized phase III trial AGITG–MAX. International Journal of Cancer, 2022, 151, 1166-1174.	5.1	1
76	Circulating tumor DNA (ctDNA) analysis by low-coverage whole genome sequencing (lcWGS) of resectable esophageal adenocarcinoma (rEAC) patients.. Journal of Clinical Oncology, 2021, 39, 4033-4033.	1.6	0
77	Association of DNA promoter hypermethylation of decoy receptor 1 (DCR1) with poor response to irinotecan in metastatic colorectal cancer.. Journal of Clinical Oncology, 2013, 31, 3552-3552.	1.6	0
78	Comparison of deep sequencing miRNA expression analysis in primary colorectal cancer and paired metastases.. Journal of Clinical Oncology, 2015, 33, e14682-e14682.	1.6	0
79	Mass spectrometry-based phosphoproteomics of tumor needle biopsies from patients (pts) with advanced solid tumors during treatment with protein kinase inhibitors.. Journal of Clinical Oncology, 2016, 34, 11609-11609.	1.6	0
80	Abstract LB-246: Detection of circulating tumor DNA in early stage cancers. , 2017, , .		0
81	Comparison of phosphoproteomic profiles in left- and right-sided colorectal cancers.. Journal of Clinical Oncology, 2019, 37, 582-582.	1.6	0
82	Triplet Chemotherapy with Cisplatin versus Oxaliplatin in the CRITICS Trial: Treatment Compliance, Toxicity, Outcomes and Quality of Life in Patients with Resectable Gastric Cancer. Cancers, 2022, 14, 2963.	3.7	0